Eli Lilly and Company (LLY)
NYSE·Healthcare·Drug Manufacturers - General
$874.10
+0.67%
Mkt Cap $869.14B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 4, 2026 | $17.94B | $19.29B | +7.51% | $6.91 | $7.54 | +9.12% | — | — |
| Q4 2025 Oct 30, 2025 | $16.05B | $17.60B | +9.64% | $5.69 | $7.02 | +23.37% | — | — |
| Q3 2025 Aug 7, 2025 | $14.70B | $15.56B | +5.80% | $5.60 | $6.31 | +12.68% | — | — |
| Q2 2025 May 1, 2025 | $12.67B | $12.73B | +0.48% | $3.26 | $3.34 | +2.45% | — | — |
| Q1 2025 Feb 6, 2025 | — | $13.53B | — | $5.03 | $5.32 | +5.77% | — | — |
| Q4 2024 Oct 30, 2024 | $12.10B | $11.44B | -5.44% | $1.47 | $1.18 | -19.73% | — | — |
| Q3 2024 Aug 8, 2024 | $9.98B | $11.30B | +13.24% | $2.60 | $3.92 | +50.77% | — | — |
| Q2 2024 Apr 30, 2024 | $8.94B | $8.77B | -1.88% | $2.46 | $2.58 | +4.88% | — | — |
| Q1 2024 Feb 6, 2024 | $8.93B | $9.35B | +4.71% | $2.22 | $2.49 | +12.16% | — | — |
| Q4 2023 Nov 2, 2023 | $8.95B | $9.50B | +6.08% | -$0.08 | $0.10 | +225.00% | — | — |
| Q3 2023 Aug 8, 2023 | $7.58B | $8.31B | +9.62% | $1.98 | $2.11 | +6.57% | — | — |
| Q2 2023 Apr 27, 2023 | $7.55B | $6.96B | -7.83% | $1.73 | $1.62 | -6.36% | — | — |
| Q1 2023 Feb 2, 2023 | $7.33B | $7.30B | -0.42% | $1.78 | $2.09 | +17.42% | — | — |
| Q4 2022 Nov 1, 2022 | $6.89B | $6.94B | +0.78% | $1.92 | $1.98 | +3.13% | — | — |
| Q3 2022 Aug 4, 2022 | $6.85B | $6.49B | -5.27% | $1.69 | $1.25 | -26.04% | — | — |
| Q2 2022 Apr 28, 2022 | $7.29B | $7.81B | +7.18% | $2.32 | $2.62 | +12.93% | — | — |
| Q1 2022 Feb 3, 2022 | $7.69B | $8.00B | +4.06% | $2.51 | $2.49 | -0.80% | — | — |
| Q4 2021 Oct 26, 2021 | $6.57B | $6.77B | +3.08% | $1.98 | $1.94 | -2.02% | — | — |
| Q3 2021 Aug 3, 2021 | $6.74B | $6.74B | +0.00% | $1.89 | $1.87 | -1.06% | — | — |
| Q2 2021 Apr 27, 2021 | $7.64B | $6.81B | -10.88% | $2.12 | $1.87 | -11.79% | — | — |